Welcome to our dedicated page for Cosmos Health SEC filings (Ticker: COSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cosmos Health Inc. (COSM) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, giving investors structured access to its official record as a Nasdaq Capital Market issuer. Cosmos Health describes itself as a diversified, vertically integrated global healthcare group, and its filings reflect activity in pharmaceuticals, nutraceuticals, manufacturing, distribution, telehealth and digital assets.
Key documents include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present audited and interim financial statements, segment information tied to wholesale distribution, pharma manufacturing and branded products, as well as discussions of risk factors, liquidity and capital resources. Notifications such as the NT 10-Q filing explain delays in periodic reports and provide context on reporting timelines.
Cosmos Health also files numerous Current Reports on Form 8-K detailing material events. Recent 8-Ks cover topics such as record quarterly results, Nasdaq minimum bid price compliance notices, entry into a Securities Purchase Agreement for up to $300 million of senior secured convertible notes, the issuance of an initial $8 million note, governance and board changes, and shareholder approvals to increase authorized share capital and authorize a potential reverse stock split. These filings help investors track financing structures, capital allocation and corporate governance decisions.
Proxy materials like the DEF 14A definitive proxy statement provide information on director elections, executive compensation, equity incentive plans and shareholder proposals, including approvals related to the note financing and changes in authorized shares. Together with Form 4 insider transaction reports referenced in company news, these documents allow users to monitor ownership changes and board-level decisions.
On Stock Titan, COSM filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight the main points of lengthy 10-K and 10-Q reports, explain complex financing terms in 8-Ks, and surface items such as bid price compliance, convertible note terms and voting outcomes. Users can quickly locate Forms 10-K, 10-Q, 8-K, DEF 14A and Form 4 filings, then rely on AI insights to understand how each filing may relate to Cosmos Health’s operations, balance sheet, governance and listing status.
Cosmos Health Inc. filed an amendment to Schedule 13G/A reporting beneficial ownership of 4,143,007.21 shares of Common Stock, representing 8.152% of the class. The filing states this percentage is based on approximately 50,824,657 shares outstanding as of April 14, 2026. The report lists Andreas Bovopoulos as the beneficial owner with sole voting and dispositive power over the reported shares.
Cosmos Health Inc. filed an amended registration statement to register 73,523,716 shares of Common Stock for resale by selling stockholders, consisting of 67,045,455 shares potentially issuable under the August 2025 Note and the Second Note and 6,478,261 shares potentially issuable under the June 2025 Note. The registration is based on maximum potential conversion at a $0.176 conversion/floor price and assumes notes and in-kind interest remain outstanding until maturity.
As of April 23, 2026, the company reported 52,617,105 shares issued and outstanding; the prospectus shows a pro forma post-offering figure of 126,054,324 shares. The Selling Stockholders will receive proceeds from resale; the company will not receive proceeds from these sales. The prospectus also discloses the company’s recently adopted digital assets treasury strategy, including prior purchases of Ethereum and Bitcoin, custodial arrangements with BitGo Prime LLC, engagement of Prime Ledger LLC, and staking plans, and highlights substantial risks, going concern disclosures, and applicable accounting (ASU 2023-08).
Cosmos Health reported record full year 2025 revenue of $65.27 million, up 20% from 2024, driven by growth across contract manufacturing, wholesale distribution and proprietary brands. Gross profit rose to $7.90 million, an 83% increase, and gross margin expanded to 12.10% from 7.92%, reflecting a richer product mix and efficiency gains.
Despite this, the company posted a GAAP net loss of $19.14 million, wider than 2024, as operating expenses climbed to $24.60 million on hiring, global expansion and large provisions for doubtful accounts. On a non-GAAP basis, Adjusted EBITDA modestly improved to $(3.36) million, while Adjusted net loss per share improved from $(0.65) to $(0.12).
Liquidity strengthened, with cash and cash equivalents increasing to $3.46 million from $0.32 million and total assets rising to $65.48 million. The company launched a digital asset treasury strategy, including a financing facility of up to $300 million and a $2 million Ethereum investment, and secured long-term manufacturing contracts covering over 12 million units. CEO Greg Siokas increased his ownership by more than 3.3 million shares.
Cosmos Health Inc. files its annual report outlining a diversified healthcare business spanning generic drugs, proprietary nutraceuticals, biocides, medical devices and telehealth. The company operates GMP- and EMA‑certified manufacturing in Greece, wholesale distribution across Europe and the UK, and a growing Sky Premium Life nutraceutical brand.
Cosmos highlights an innovation‑focused pipeline, including CCX0722, an obesity and weight‑management hydrogel product targeted for a third or fourth quarter 2026 market launch, and several oncology programs backed by WIPO patents and exclusive licenses. It also acquired the AI‑driven Cloudscreen drug‑repurposing platform and filed multiple patent applications for neurological and hematologic indications.
The report notes 2025 inventory of $5.8 million, geographically concentrated revenues in Greece, and a workforce of 163 employees. During 2025, Cosmos used an at‑the‑market share program, equity compensation plans and debt‑for‑equity exchanges to raise capital, settle obligations and fund R&D initiatives and growth strategy.
Cosmos Health Inc. disclosure shows Andreas Bovopoulos beneficially owns 3,733,412 shares of common stock, representing 9.974% of the class. The percentage is calculated against approximately 37,432,522 shares outstanding as of February 24, 2026.
The filing states Mr. Bovopoulos has sole voting power and sole dispositive power over the 3,733,412 shares. This entry appears as an amendment to a prior Schedule 13G/A and records beneficial ownership at the disclosed level.
Cosmos Health Inc. CEO, director and 10% owner Grigorios Siokas acquired 388,532 shares of common stock on February 12, 2026. The shares were issued at $0.3732 per share in exchange for $145,000 of debt the company owed to him. Following this transaction, he directly owns 8,861,914 shares of Cosmos Health common stock.
Cosmos Health Inc. Chief Executive Officer, director and 10% owner Grigorios Siokas acquired 291,262 shares of common stock on February 11, 2026. The shares were obtained at $0.4120 per share in exchange for $120,000 of debt the company owed to him under a debt exchange agreement.
Following this transaction, Mr. Siokas directly beneficially owns 8,473,382 shares of Cosmos Health common stock.
Cosmos Health Inc. filed a Form 4 showing that CEO, director and 10% owner Grigorios Siokas acquired additional common shares through a debt-for-equity exchange. On January 23, 2026, he obtained 90,325 shares of common stock at $0.4982 per share, representing the fair market value that day, in exchange for $45,000 of debt the company owed him under a Debt Exchange Agreement. Following this transaction, he directly holds 8,182,120 common shares.
Cosmos Health Inc.'s Chief Executive Officer, director, and 10% owner Grigorios Siokas acquired additional common shares of the company through a debt exchange. On January 20, 2026, he obtained 353,321 shares of common stock at $0.4953 per share, described as the fair market value on that date. The shares were issued under a Debt Exchange Agreement in which $175,000 of debt the company owed to Mr. Siokas was exchanged for equity.
Following this transaction, Mr. Siokas beneficially owns 8,091,795 shares of Cosmos Health common stock in direct ownership. The filing characterizes the transaction with code "P" and notes that these shares are classified as Exchange Shares under the terms of the Debt Exchange Agreement.